Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)

A pharmaceutical composition comprising at least a first siRNA molecule that targets a conserved region of an ORF1AB gene of the Wuhan seafood market novel pneumonia 2019 Novel Coronavirus (2019-nCoV) genome, and at least a second siRNA that targets a conserved region of an N-protein gene of said 2019-nCoV genome, wherein said composition comprises a pharmaceutically acceptable carrier, wherein said carrier comprises a polymeric nanoparticle and/or a liposomal nanoparticle carrier, wherein the composition further comprises a combination of two sense strands, one from each of said first and second siRNA molecules, and said combination is selected from the group consisting of:

• CoV3 and CoV18
• CoV3 and CoV14
• CoV4 and CoV14 and
• CoV4 and CoV18,
• respectfully, wherein CoV3 has the sequence GGAAGGAAGTTCTGTTGAA (SEQ ID NO:
• 401) or GGAAGGAAGTTCTGTTGAATTAAAA (SEQ ID NO:
• 402), CoV4 comprises the sequence GCCATTAGTGCAAAGAATA (SEQ ID NO:
• 403), CoV-14 has the sequence GGCCGCAAATTGCACAATT (SEQ ID NO:
• 404), and CoV18 has the sequence CCACCAACAGAGCCTAAAA (SEQ ID NO:
• 405) or CCACCAACAGAGCCTAAAAAGGACA (SEQ ID NO:
• 406).